Loading…

The burden of skeletal-related events in patients with prostate cancer and bone metastasis

Abstract Background To assess contemporary characteristics, hospital admissions, charges, and mortality in patients with prostate cancer (CaP) who have bone metastases and skeletal-related events in an observational study. Methods Relying on the Nationwide Inpatient Sample (NIS), patients with CaP w...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2015-01, Vol.33 (1), p.17.e9-17.e18
Main Authors: Roghmann, Florian, M.D, Antczak, Carina, M.D, McKay, Rana R., M.D, Choueiri, Toni, M.D, Hu, Jim C., M.D, Kibel, Adam S., M.D, Kim, Simon P., M.D, Kowalczyk, Keith J., M.D, Menon, Mani, M.D, Nguyen, Paul L., M.D, Saad, Fred, M.D, Sammon, Jesse D., M.D, Schmid, Marianne, M.D, Sukumar, Shyam, M.D, Sun, Maxine, B.Sc, Noldus, Joachim, M.D, Trinh, Quoc-Dien, M.D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background To assess contemporary characteristics, hospital admissions, charges, and mortality in patients with prostate cancer (CaP) who have bone metastases and skeletal-related events in an observational study. Methods Relying on the Nationwide Inpatient Sample (NIS), patients with CaP with bone metastases between 1998 and 2010 were abstracted. Patients who experienced skeletal-related events were identified, and hospital charges were calculated. Generalized linear regression analyses focused on in-hospital mortality. Results Between 1998 and 2010, a weighted estimate of 443,929 CaP visits with bone metastases was recorded. Of these, 15.9% experienced at least 1 SRE. The rate of SRE decreased from 18% to 15.4% (1998–2010, estimated annual percent change [EAPC] =−1.44%, P = 0.005) and the SRE-associated mortality decreased from 8.5% to 4.7% (1998–2010, EAPC =−3.68%, P = 0.004). Nevertheless, the inflation-adjusted charges associated with hospital visits of patients with CaP with bone metastases rose by 92% to $1,512,449,106 (EAPC = +8.82%, P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2014.09.010